After gains of 6.6% this afternoon, Neurocrine Biosciences shares are now trading at $116.86. Read below for the essential facts about this stock:
-
Neurocrine Biosciences has logged a 14.0% 52 week change, compared to 15.0% for the S&P 500
-
NBIX has an average analyst rating of buy and is -7.51% away from its mean target price of $126.35 per share
-
Its trailing earnings per share (EPS) is $1.79, which brings its trailing Price to Earnings (P/E) ratio to 65.3. The Health Care sector's average P/E ratio is 24.45
-
The company's forward earnings per share (EPS) is $4.8 and its forward P/E ratio is 24.3
-
The company has a Price to Book (P/B) ratio of 6.15 in contrast to the Health Care sector's average P/B ratio is 4.16
-
The current ratio is currently 4.0, which consists in its liquid assets divided by any liabilities due within in the next 12 months
-
The company's free cash flow for the last fiscal year was $355.9 Million and the average free cash flow growth rate is 0.0%
-
Neurocrine Biosciences's revenues have an average growth rate of 0.0% with operating expenses growing at -68.8%. The company's current operating margins stand at 16.7%